Nature Communications (Aug 2020)
GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer
- Qin Wu,
- Wail ba-alawi,
- Genevieve Deblois,
- Jennifer Cruickshank,
- Shili Duan,
- Evelyne Lima-Fernandes,
- Jillian Haight,
- Seyed Ali Madani Tonekaboni,
- Anne-Marie Fortier,
- Hellen Kuasne,
- Trevor D. McKee,
- Hassan Mahmoud,
- Michelle Kushida,
- Sarina Cameron,
- Nergiz Dogan-Artun,
- WenJun Chen,
- Yan Nie,
- Lan Xin Zhang,
- Ravi N. Vellanki,
- Stanley Zhou,
- Panagiotis Prinos,
- Bradly G. Wouters,
- Peter B. Dirks,
- Susan J. Done,
- Morag Park,
- David W. Cescon,
- Benjamin Haibe-Kains,
- Mathieu Lupien,
- Cheryl H. Arrowsmith
Affiliations
- Qin Wu
- Structural Genomics Consortium, University of Toronto
- Wail ba-alawi
- Princess Margaret Cancer Centre, University Health Network
- Genevieve Deblois
- Princess Margaret Cancer Centre, University Health Network
- Jennifer Cruickshank
- The Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre
- Shili Duan
- Princess Margaret Cancer Centre, University Health Network
- Evelyne Lima-Fernandes
- Structural Genomics Consortium, University of Toronto
- Jillian Haight
- The Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre
- Seyed Ali Madani Tonekaboni
- Princess Margaret Cancer Centre, University Health Network
- Anne-Marie Fortier
- Goodman Cancer Research Centre, McGill University
- Hellen Kuasne
- Goodman Cancer Research Centre, McGill University
- Trevor D. McKee
- Princess Margaret Cancer Centre, University Health Network
- Hassan Mahmoud
- Princess Margaret Cancer Centre, University Health Network
- Michelle Kushida
- Developmental and Stem Cell Biology Program and Arthur and Sonia Labatt Brain tumor Research Centre, The Hospital for Sick Children
- Sarina Cameron
- Princess Margaret Cancer Centre, University Health Network
- Nergiz Dogan-Artun
- Princess Margaret Cancer Centre, University Health Network
- WenJun Chen
- Structural Genomics Consortium, University of Toronto
- Yan Nie
- Structural Genomics Consortium, University of Toronto
- Lan Xin Zhang
- Structural Genomics Consortium, University of Toronto
- Ravi N. Vellanki
- Princess Margaret Cancer Centre, University Health Network
- Stanley Zhou
- Princess Margaret Cancer Centre, University Health Network
- Panagiotis Prinos
- Structural Genomics Consortium, University of Toronto
- Bradly G. Wouters
- Princess Margaret Cancer Centre, University Health Network
- Peter B. Dirks
- Developmental and Stem Cell Biology Program and Arthur and Sonia Labatt Brain tumor Research Centre, The Hospital for Sick Children
- Susan J. Done
- The Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre
- Morag Park
- Goodman Cancer Research Centre, McGill University
- David W. Cescon
- The Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre
- Benjamin Haibe-Kains
- Princess Margaret Cancer Centre, University Health Network
- Mathieu Lupien
- Princess Margaret Cancer Centre, University Health Network
- Cheryl H. Arrowsmith
- Structural Genomics Consortium, University of Toronto
- DOI
- https://doi.org/10.1038/s41467-020-18020-8
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 12
Abstract
Triple negative breast cancer is a deadly form of breast cancer with limited therapeutic options. Here the authors show the efficacy of GLUT1 pharmacological inhibition against a subset of tumors expressing RB1, thereby identifying RB1 protein level as a biomarker of sensitivity to anti-GLUT1 therapy.
